| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a naturally occurring naphthoquinone derivative. –Plumbagin can undergo redox cycling to generate reactive oxygen species (ROS) -apototosis, activation of caspases, modulation of Bax, Bcl‑2, loss of MMP. -Cell cycle arrest in cancer cells, often at the G0/G1, or G2/M phases. -May inhibit NF‑κB activation – MAPK Pathways – PI3K/Akt Pathway -Downregulation of (VEGF) and matrix metalloproteinases (MMPs). -Seems capable of raising ROS in normal and cancer cells (#2004) -ic50 cancer cells 1-10uM, normal cells >10uM
|
| Source: |
| Type: |
| Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin. EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin). EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis. |
| 5163- | PLB, | Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:299 Target#:96 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid